Half-Life Cancer Research Results
Half-Life, Half-Life: Click to Expand ⟱
| Source: |
| Type: |
For many drugs, the half-life is the time it takes for half of the drug’s active substance to be eliminated from the bloodstream.
In medicine, knowing a drug’s half-life helps in designing treatment regimens that reduce adverse effects.
|
Scientific Papers found: Click to Expand⟱
*BioAv↓, Half-Life∅, *BioAv↓, Dose∅, eff↑, CYP1A2↓, CYP2C9↓, CYP3A4↓,
TumCP↓, TumCCA↑, Apoptosis↑, MMPs↓, Akt↓, *BioAv↑, *BioAv↓, Half-Life∅, Hif1a↓, GLUT1↓, VEGF↓, ChemoSen↑, ROS↑, Bcl-2↓, Bcl-xL↓, BAX↑, BIM↑,
AntiCan↑, TumCG↓, angioG↓, TumMeta↓, BioAv↓, BioAv↓, BioAv↑, selectivity↑, EPR↑, eff↓, ChemoSen↑, Dose∅, Half-Life∅, eff↑,
PDKs↓, PDH↑, lactateProd↓, Half-Life∅,
*Dose∅, Half-Life∅, BioAv∅, BBB↑, toxicity∅, eff↓, Apoptosis↑, Casp3↑, Cyt‑c↑, cl‑PARP↑, DNMTs↓, Telomerase↓, angioG↓, Hif1a↓, NF-kB↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, IGF-1↓, H3↓, HDAC1↓, *LDH↓, *ROS↓,
TumCCA↑, BioAv↑, Half-Life∅, TNF-α↓, Casp8↑, BAX↑, Bak↑, EGF↓, mTOR↓, PI3K↓, ERK↓, Akt↓, NF-kB↓, VEGF↓, angioG↓, antiOx↑, EMT↓, OS↑, MAPK↓, ChemoSen↑, MMP9↓, MMP2↓, ROS↑, ROS↑, GSH↓, Casp3↑, ROS↑,
| - |
in-vivo, |
Colon, |
NA |
|
|
|
- |
Human, |
Nor, |
NA |
|
|
|
TumCG↓, HDAC↓, *BioAv↑, Dose∅, Half-Life∅,
Showing Research Papers: 1 to 7 of 7
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 7
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
antiOx↑, 1, GSH↓, 1, ROS↑, 4,
Mitochondria & Bioenergetics(tgid=3) ⓘ
EGF↓, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
CYP3A4↓, 1, lactateProd↓, 1, PDH↑, 1, PDKs↓, 1,
Cell Death(tgid=5) ⓘ
Akt↓, 2, Apoptosis↑, 2, Bak↑, 2, BAX↑, 3, Bcl-2↓, 2, Bcl-xL↓, 2, BIM↑, 1, Casp3↑, 2, Casp8↑, 1, Cyt‑c↑, 1, MAPK↓, 1, Telomerase↓, 1,
Transcription & Epigenetics(tgid=7) ⓘ
H3↓, 1,
DNA Damage & Repair(tgid=10) ⓘ
DNMTs↓, 1, P53↑, 1, cl‑PARP↑, 1,
Cell Cycle & Senescence(tgid=11) ⓘ
TumCCA↑, 2,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
EMT↓, 1, ERK↓, 1, HDAC↓, 1, HDAC1↓, 1, IGF-1↓, 1, mTOR↓, 1, PI3K↓, 1, PTEN↑, 1, TumCG↓, 2,
Migration(tgid=13) ⓘ
MMP2↓, 1, MMP9↓, 1, MMPs↓, 2, TumCP↓, 1, TumMeta↓, 1,
Angiogenesis & Vasculature(tgid=14) ⓘ
angioG↓, 3, EPR↑, 1, Hif1a↓, 2, VEGF↓, 2,
Barriers & Transport(tgid=15) ⓘ
BBB↑, 1, GLUT1↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
NF-kB↓, 2, TNF-α↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↓, 2, BioAv↑, 2, BioAv∅, 1, ChemoSen↑, 3, CYP1A2↓, 1, CYP2C9↓, 1, Dose∅, 3, eff↓, 2, eff↑, 2, Half-Life∅, 7, selectivity↑, 1,
Functional Outcomes(tgid=23) ⓘ
AntiCan↑, 1, OS↑, 1, toxicity∅, 1,
Total Targets: 61
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
ROS↓, 1,
Core Metabolism/Glycolysis(tgid=4) ⓘ
LDH↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↓, 3, BioAv↑, 2, Dose∅, 1,
Clinical Biomarkers(tgid=22) ⓘ
LDH↓, 1,
Total Targets: 6
Scientific Paper Hit Count for: Half-Life, Half-Life
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:0 prod#:% Target#:1109 State#:% Dir#:6
wNotes=0 sortOrder:rid,rpid
Home Page